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Background: Bivalirudin monotherapy provides a similar protection from ischemic events in patients undergoing PCI while lowering the risk of 
bleeding in comparison to heparin plus GP IIb/IIIa blockade. However, bivalirudin monotherapy may not be as efficacious as heparin plus GP IIb/IIIa 
inhibition in patients undergoing PCI for ACS.
Methods: Electronic searches were conducted of all published studies reporting on the efficacy and safety of bivalirudin monotherapy in ACS in 
comparison to heparin plus GP IIb/IIIa blockade. A meta-analysis was performed with major bleeding and MACE as the primary endpoints.
Results: We identified 7 studies, involving 22,034 patients published between 1995 and 2009. MACE was similar in both bivalirudin monotherapy 
and heparin plus GP IIb/IIIa blockade groups (6.8% vs. 6.9%; OR 1.04 (95% CI 0.93 to 1.16), p=0.49 (Figure). The results showed no heterogeneity 
among the trials (Q-test: 6.12; I2: 2%; p=0.41). No publication bias was detected (Egger’s test: p=0.35). Major bleeding in patients receiving 
bivalirudin monotherapy was significantly lower than in those receiving heparin plus GP IIb/IIIa blockade (2.7% vs. 5.3%; OR 0.48 (95% CI 0.38 to 
0.61), p< 0.01. 
Conclusion: The current meta-analysis indicates that bivalirudin monotherapy for patients undergoing PCI due to ACS provides similar efficacy in 
reducing ischemic events, while decreasing the incidence of major bleeding by ~50% in comparison to heparin plus GP IIb/IIIa blockade.
